Cardio

HeartMate mechanical circulatory support device implantation will benefit from Thoratec’s acquisition of transapical access specialist Apica Cardiovascular.

Thoratec Corporation has started its CE Mark Clinical Trial for HeartMate III™ and has seen a first patient implanted with the new device.

Human-machine interface specialist PixArt Imaging Inc., has announced the release of its Heart Rate Monitor sensor for smart phones and wearable device platforms.

Inspire MD has modified its MGuard Prime Embolic Protection Stent in order to address dislodgement issues. The EU authorities have given them the nod to return it to the market.

After its main competitor gained approval last week, now Edwards has its own reason to celebrate as the next generation Sapien XT gets the FDA’s nod.

With a combined revenue of $27 Billion, the acquisition of Covidien by Medtronic makes for one helluva company that promises to have fingers in every conceivable medtech pie.

Strong clinical results from Medtronic’s pivotal CoreValve High Risk study have persuaded the FDA to extend its approval to include patients at high risk for conventional surgery.

HeartWare International tells us it will respond to the FDA over its warning letter, and has resolution of the matters raised well in hand.

TriReme’s Chocolate Catheter gets Coronary indication

STENTYS is to acquire the assets of Cappella Peel Away Inc to enhance delivery of its next Self-Apposing Stent

According to a new study, ICDs have for the first time been found to be associated with improved survival among heart failure patients whose left ventricles only pump 30 to 35 percent of blood out of the heart with each contraction.

Cardiovascular Systems, Inc. points us at one-year data and a new economic analysis from its ORBIT II coronary study in a late-breaker session at the Society for Cardiovascular Angiography and Interventions (SCAI) 2014 conference last week.

St. Jude Medical, Inc. has completed its acquisition of CardioMEMS, Inc., developer of the CardioMEMS™ HF System. The acquisition was completed on May 30, 2014.

New data presented at EuroPCR 2014 in Paris suggests impressive performance at six months for the Lotus™ Valve System, with 79.8 percent of patients showing no paravalvular aortic regurgitation at six months with no cases of severe paravalvular aortic regurgitation in any patient.

OrbusNeich’s novel COMBO™ Dual Therapy Stent has been shown in a three year study to actively promote rapid endothelialization and deliver long-term, true vessel healing with no thrombotic events reported.

Direct Flow Medical tells us about positive 12 month outcomes from the DISCOVER CE Mark Trial. Results were featured at this week’s EuroPCR in an oral presentation by principal investigator Joaquim Schofer, MD, from the Medical Care Center, Hamburg, Germany.